Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Csl ADR CSLLY

Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Add To Watchlist

Recent & Breaking News (OTCQX:CSLLY)

CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019

PR Newswire July 1, 2019

CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting

PR Newswire June 20, 2019

Haemonetics To Transfer Union, South Carolina, Manufacturing Facility To CSL Plasma Inc.

PR Newswire May 14, 2019

CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]

PR Newswire April 25, 2019

Japan's Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

PR Newswire March 26, 2019

CSL Behring Extends Support of World Federation of Hemophilia Programs

PR Newswire February 4, 2019

CSL Named One of the Best Employers in the US for Diversity

PR Newswire January 16, 2019

Global Biotech Leader CSL to Present at J.P. Morgan Healthcare Conference on Wednesday, January 9

PR Newswire January 7, 2019

CSL CEO Paul Perreault Earns 2018 Most Admired CEOs Recognition from the Philadelphia Business Journal

PR Newswire December 6, 2018

Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines

PR Newswire November 16, 2018

Seqirus Releases Real-World Data Indicating Significantly Greater Effectiveness of Cell-Based Seasonal Influenza Vaccines Compared to Standard Influenza Vaccine Options

PR Newswire November 16, 2018

Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.

PR Newswire October 23, 2018

Seqirus Presents Data at IDWeek Demonstrating Cell-Derived Viruses Have a Closer Match to Circulating Influenza Viruses Compared to Egg-derived Viruses Used in the Production of Influenza Vaccines

PR Newswire October 3, 2018

Seqirus Presents Favorable Outcomes Data for Adjuvanted Trivalent Influenza Vaccine (FLUAD®) at 6th Annual IDWeek

PR Newswire October 3, 2018

CSL Named One of the Top Companies in the World for Diversity and Inclusion

PR Newswire September 18, 2018

Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process

PR Newswire August 23, 2018

IDELVION® 3500 IU Vials Now Available to Provide Convenience to Patients

PR Newswire August 23, 2018

GISAID announces a major contribution from Seqirus to support open and rapid sharing of influenza virus data

PR Newswire Asia July 26, 2018

A New Generation Of Coagulation Specialists Is Advancing Research With Support From CSL Behring Global Grant

PR Newswire June 22, 2018

IDELVION® Newly Approved 3500 IU Vial to Provide Convenience to Patients Using Larger Volumes

PR Newswire May 31, 2018